We are live on ! Find out more
GCGM

General Catalyst Group Management Portfolio holdings

AUM $184M
1-Year Est. Return 50.45%
This Fund
S&P 500
This Quarter Est. Return
+12.68%
1 Year Est. Return
+50.45%
3 Year Est. Return
+205.57%
5 Year Est. Return
+78.87%
10 Year Est. Return
AUM
$1.3B
AUM Growth
+$27M
Cap. Flow
-$104M
Cap. Flow %
-8.01%
Top 10 Hldgs %
99.98%
Holding
11
New
1
Increased
Reduced
2
Closed

Top Buys

Rank Stock Value
1
AVBP icon
ArriVent BioPharma
AVBP
+$30.1M

Top Sells

Rank Stock Value
1
IOT icon
Samsara
IOT
+$134M
2
VRM icon
Vroom Inc
VRM
+$20

Sector Composition

Rank Sector Weight
1 Technology 82.32%
2 Healthcare 10.39%
3 Industrials 3.7%
4 Consumer Discretionary 3.55%
5 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IOT icon
1
Samsara
IOT
$22.9B
$994M 76.49%
26,297,056
-3,943,716
-13% -$134M
WRBY icon
2
Warby Parker
WRBY
$3.13B
$77M 5.93%
5,656,571
GTLB icon
3
GitLab
GTLB
$5.86B
$53.7M 4.14%
921,405
EVLV icon
4
Evolv Technologies
EVLV
$995M
$48M 3.7%
10,796,148
CART icon
5
Maplebear
CART
$10.8B
$45.9M 3.53%
1,230,549
OSCR icon
6
Oscar Health
OSCR
$9.36B
$31.3M 2.41%
2,107,719
AVBP icon
7
ArriVent BioPharma
AVBP
$1.36B
$26.7M 2.05%
+1,494,786
New +$30.1M
PET
8
DELISTED
Wag!
PET
$13.8M 1.06%
6,976,530
CMRC
9
Commerce.com Inc Series 1
CMRC
$263M
$8.27M 0.64%
1,200,000
VRM icon
10
Vroom Inc
VRM
$37.5M
$512K 0.04%
38,145
-1
-0% -$20
CZOO
11
DELISTED
Cazoo Group Ltd
CZOO
$207K 0.02%
17,211

Similar funds

General Catalyst Group Management's Q1 2024 Portfolio in Review

As of Q1 2024, General Catalyst Group Management held 11 positions worth $1.3B, up 2.1% from $1.27B the previous quarter. Its ten largest holdings account for 100% of the portfolio.

General Catalyst Group Management withdrew a net $104M in Q1 2024, reducing 2 holdings. Its largest reduction was Samsara, cutting an estimated $134M.

By sector, the portfolio is most concentrated in Technology at 82% of assets, down from 86% a quarter earlier, followed by Healthcare and Industrials.

Against the trend, General Catalyst Group Management opened a new position in ArriVent BioPharma worth $26.7M.

  • General Catalyst Group Management's largest Q1 2024 buy was ArriVent BioPharma: 1,494,786 shares worth $26.7M.
  • General Catalyst Group Management's biggest Q1 2024 reduction was Samsara, cutting an estimated $134M.
  • General Catalyst Group Management's ten largest holdings make up 100% of its $1.3B portfolio in Q1 2024.
  • General Catalyst Group Management opened 1 new position and closed 0 in Q1 2024.
  • General Catalyst Group Management's portfolio value rose 2.1% quarter-over-quarter to $1.3B.

Based on General Catalyst Group Management's 13F filing for Q1 2024, filed 10 May 2024.